Hemostasis Clinical Research Network Protocols

止血临床研究网络协议

基本信息

批准号：
8138425
负责人：
CINDY A LEISSINGER
金额：
$ 1.58万
依托单位：
TULANE UNIVERSITY OF LOUISIANA
依托单位国家：
美国
项目类别：
财政年份：
2002
资助国家：
美国
起止时间：
2002-09-30 至 2013-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8138425
关键词：
Address American Society of Hematology Area Award B-Lymphocytes Blood Blood Banks Blood Coagulation Disorders Blood Platelet Disorders Blood specimen Bone Marrow Bone Marrow Transplantation Caring Censuses Centers for Disease Control and Prevention (U.S.)Cities Clinic Clinical Research Clinical Trials Clinical Trials Network Contracts Development Disease Enrollment Ensure Faculty Family Fellowship Financial Support Floods Foundations Funding Future Grant Health Sciences Hematology Hemophilia A Hemorrhage Hemostatic function Home environment Hospitals Human Resources Hurricane Immune response Industry Institutes Intervention Investigation K-Series Research Career Programs Laboratories Lead Left Location Louisiana Mediation Medical Medicine Mentors Monitor National Heart, Lung, and Blood Institute Outpatients Patients Pennsylvania Pharmaceutical Preparations Play Process Protocols documentation Research Research Infrastructure Research Personnel Research Training Rest Risk Role Services Site Staging Study Subject T-Lymphocyte Transfusion United States National Institutes of Health Universities Visit Work base blood product clinical care expectation implementation trial inhibitor/antagonist leukemia meetings member oncology patient oriented prevent professor programs protocol development response rituximab working group

项目摘要

DESCRIPTION (provided by applicant) Patients with disorders of hemostasis are subject to long term problems and risks, difficult treatment decisions and risks associated with treatment itself. Many of these risks and complications can be lessened or prevented by appropriate intervention strategies. Advances in the management of patients with bleeding disorders and those requiring transfusions require: 1) that clinical studies utilize a multi-institutional cooperative network in order to accrue sufficient numbers of patients to achieve meaningful answers; and 2) that patients receive specialized clinical care while participating in such trials. The Transfusion Medicine/Hemostasis (TMH) Clinical Trials Network was initiated in October, 2002. Tulane University Health Sciences Center is one of the 17 core sites that comprise the clinical trials network. The Tulane core site was developed using the basic infrastructure and services of the Louisiana Center for Bleeding and Clotting Disorders which cares for over 400 patients with disorders of hemostasis, and serves a role in the accrual of patients with bleeding disorders as well as in their clinical care .while participating in clinical trials. In addition, the Tulane Bone Marrow Transplant Unit plays an important role in the implementation of transfusion medicine trials at the Tulane site. The PI and Co-Pi's from the Tulane site have played an integral role in the development of the network during it's initial 5 year period, and in the development and implementation of network studies. The purpose of this project at the Tulane site is to continue full participation in TMH network activities, both in the implementation of trials developed during the initial grant period as well as in the development of new protocols to be implemented in the network during the second 5 year award period.

描述（由申请人提供）患有止血障碍的患者面临长期问题和风险、困难的治疗决策以及与治疗本身相关的风险。许多这些风险和并发症可以通过适当的干预策略来减轻或预防。出血性疾病患者和需要输血患者的管理取得进展需要：1）临床研究利用多机构合作网络，以积累足够数量的患者以获得有意义的答案； 2) 患者在参与此类试验时接受专门的临床护理。输血医学/止血 (TMH) 临床试验网络于 2002 年 10 月启动。杜兰大学健康科学中心是组成该临床试验网络的 17 个核心站点之一。杜兰大学核心站点是利用路易斯安那州出血和凝血疾病中心的基本基础设施和服务开发的，该中心照顾 400 多名患有止血疾病的患者，并在出血性疾病患者的累积及其临床治疗中发挥作用。参与临床试验时的护理。此外，杜兰骨髓移植中心在杜兰中心实施输血医学试验中发挥着重要作用。杜兰大学的 PI 和 Co-Pi 在网络最初 5 年的发展以及网络研究的开发和实施中发挥了不可或缺的作用。杜兰大学站点的该项目的目的是继续全面参与 TMH 网络活动，包括实施初始资助期间开发的试验以及开发将在后 5 个网络中实施的新协议。年奖励期。